礼来阿尔茨海默病药物最新研究：早期使用记能达可降低病情变重风险

格隆汇2025-08-02

据每经，近日，“2025阿尔茨海默病协会国际会议（AAIC）”在加拿大多伦多召开，跨国制药巨头礼来在会上公布了去年获批新药——记能达（通用名：多奈单抗注射液）三期临床研究的长期扩展（LTE）结果。数据显示，相比阿尔茨海默病神经影像计划（ADNI）数据库中外部未经治疗的队列，接受记能达治疗的研究参与者的疾病进展显著减缓，获益在三年间持续增强。更值得注意的是，与延迟治疗组相比，早期使用记能达的研究...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556823949?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-02 19:08","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2556823949","market":"hk","top_or_hot":-1,"title":"礼来阿尔茨海默病药物最新研究：早期使用记能达可降低病情变重风险","media":"格隆汇","content":"<div>\n<p>据每经，近日，“2025阿尔茨海默病协会国际会议（AAIC）”在加拿大多伦多召开，跨国制药巨头礼来在会上公布了去年获批新药——记能达（通用名：多奈单抗注射液）三期临床研究的长期扩展（LTE）结果。数据显示，相比阿尔茨海默病神经影像计划（ADNI）数据库中外部未经治疗的队列，接受记能达治疗的研究参与者的疾病进展显著减缓，获益在三年间持续增强。更值得注意的是，与延迟治疗组相比，早期使用记能达的研究...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来阿尔茨海默病药物最新研究：早期使用记能达可降低病情变重风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来阿尔茨海默病药物最新研究：早期使用记能达可降低病情变重风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-02 19:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据每经，近日，“2025阿尔茨海默病协会国际会议（AAIC）”在加拿大多伦多召开，跨国制药巨头礼来在会上公布了去年获批新药——记能达（通用名：多奈单抗注射液）三期临床研究的长期扩展（LTE）结果。数据显示，相比阿尔茨海默病神经影像计划（ADNI）数据库中外部未经治疗的队列，接受记能达治疗的研究参与者的疾病进展显著减缓，获益在三年间持续增强。更值得注意的是，与延迟治疗组相比，早期使用记能达的研究...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2552382058.USD","symbol_name":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2556823949","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556823949","pubTimestamp":1754132900,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"据每经，近日，“2025阿尔茨海默病协会国际会议（AAIC）”在加拿大多伦多召开，跨国制药巨头礼来在会上公布了去年获批新药——记能达（通用名：多奈单抗注射液）三期临床研究的长期扩展（LTE）结果。数据","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1548497426.USD":"安联环球人工智能AT Acc","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","AAIC":"阿灵顿资产投资公司","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LLY":"礼来","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","01477":"欧康维视生物-B","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS"},"translate_title":"The latest research on Eli Lilly's Alzheimer's disease drugs: Early use of Ginunda can reduce the risk of severe disease","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"01477":1,"AAIC":1},"content_text":"据每经，近日，“2025阿尔茨海默病协会国际会议（AAIC）”在加拿大多伦多召开，跨国制药巨头礼来在会上公布了去年获批新药——记能达（通用名：多奈单抗注射液）三期临床研究的长期扩展（LTE）结果。数据显示，相比阿尔茨海默病神经影像计划（ADNI）数据库中外部未经治疗的队列，接受记能达治疗的研究参与者的疾病进展显著减缓，获益在三年间持续增强。更值得注意的是，与延迟治疗组相比，早期使用记能达的研究参与者，其疾病进展至下一阶段的风险显著降低27%，这意味着早筛早诊仍是破解这一老年病治疗困局的关键。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556823949","isCrawlerRequest":true}